pf-01367338

brca2 Mutation Carrier

Cancer Research UKPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

31 Active assets in the brca2 Mutation Carrier cohort.

Asset / Sponsor	Phase	Rating
Olaparib M.D. Anderson Cancer Center	Phase 3	BB
Veliparib The University of Texas Health Science Center at San Antonio	Phase 2	BB
Olaparib GBG Forschungs GmbH	Phase 3	BB
Talzenna Brown University	Phase 3	BB
Ovitrelle University Hospital, Ghent	Phase 4	BB

View all 50 →

Same molecule, other indications

pf-01367338 is also rated in:

hereditary breast ovarian cancer syndromeDormant

B

Indicative ·

57 / 100

breast cancerDormant

CCC

Indicative ·

48 / 100

ovarian cancerDormant

CCC

Indicative ·

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.